Assessment of the Proton Pump Inhibitor, Esomeprazole Magnesium Hydrate and Trihydrate, on Pathophysiological Markers of Preeclampsia in Preclinical Human Models of Disease

Assessment of the Proton Pump Inhibitor, Esomeprazole Magnesium Hydrate and Trihydrate, on Pathophysiological Markers of Preeclampsia in Preclinical Human Models of Disease

Previously, we demonstrated that the proton pump inhibitor, esomeprazole magnesium hydrate (MH), could have potential as a repurposed treatment against preeclampsia, a serious obstetric condition. In this study we investigate the difference in the preclinical effectiveness between 100 µM of esomepra...

Full description

Bibliographic Details
Main Authors: Natasha de Alwis, Bianca R. Fato, Sally Beard, Natalie K. Binder, Tu’uhevaha J. Kaitu’u-Lino, Kenji Onda, Natalie J. Hannan
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:International Journal of Molecular Sciences
Subjects:
preeclampsia
placenta
esomeprazole
trophoblast
sFLT-1
Online Access:https://www.mdpi.com/1422-0067/23/17/9533

Internet

https://www.mdpi.com/1422-0067/23/17/9533

Similar Items